Printer Friendly

Dare Bioscience announces effective license, collaboration pact for SST-6007.

Dare Bioscience announced that it has met the funding requirement for obtaining an exclusive worldwide license to advance SST-6007, a potential treatment for Female Sexual Arousal Disorder, or FSAD. Dare announced a license and development agreement with Strategic Science & Technologies to develop SST-6007 earlier this week. Dare plans to pursue the 505(b)(2) regulatory pathway for SST-6007 in the U.S. and leverage the existing data and established safety profile of the Viagra brand. Dare anticipates commencing a Phase 2b clinical trial in the second half of 2018 utilizing the proceeds from the investment that closed today, the company stated.

COPYRIGHT 2018 The Fly
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:The Fly
Date:Feb 15, 2018
Previous Article:Hyatt sees FY18 adjusted EBITDA $805M-$825M.
Next Article:Analysts caution against overreacting to Biogen's Alzheimer's trial change.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters